Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An analgesic and pyrazolone derivative which inhibits prostaglandin synthesis. It has been used as an analgesic and systemic antipyretic but given the frequency and severity of its side effects, the majority of products currently on the market are made for dermatological or otological topical application.
TOPICAL USE: The small dose and low plasma absorption of most topical dermatological and otic preparations make it unlikely that it will transfer into breastmilk in significant amounts. Topical use is compatible with breastfeeding.
Systemic use (orally) is contraindicated during breastfeeding:
Administered orally to mothers, it is excreted in breastmilk in amounts which could be significant.(Berlin 1982)
Hemolytic anemia has been observed in a newborn whose mother was taking a phenazone derivative. (Frei 1985)